Wedbush reissued their outperform rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Thursday, RTT News reports. Wedbush currently has a $13.00 target price on the stock.
Several other analysts also recently weighed in on SYRS. BidaskClub upgraded shares of Syros Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Friday, March 22nd. Piper Jaffray Companies cut their price objective on shares of Syros Pharmaceuticals from $28.00 to $24.00 and set an overweight rating on the stock in a research report on Wednesday, April 10th. ValuEngine downgraded shares of Syros Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, January 2nd. Oppenheimer set a $13.00 price objective on shares of Syros Pharmaceuticals and gave the company a buy rating in a research report on Thursday, March 7th. Finally, HC Wainwright reiterated a hold rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research report on Friday, March 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $16.38.
NASDAQ:SYRS traded up $0.03 during mid-day trading on Thursday, hitting $6.97. The stock had a trading volume of 1,458 shares, compared to its average volume of 181,880. The company has a market cap of $227.40 million, a PE ratio of -3.69 and a beta of 1.30. Syros Pharmaceuticals has a 52 week low of $5.17 and a 52 week high of $13.73.
In related news, Director Srinivas Akkaraju bought 533,332 shares of the stock in a transaction on Tuesday, April 9th. The shares were purchased at an average price of $7.50 per share, with a total value of $3,999,990.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Venture Fund Vii L.P. Arch sold 167,503 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $7.83, for a total transaction of $1,311,548.49. The disclosure for this sale can be found here. 27.80% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in SYRS. BlackRock Inc. grew its stake in shares of Syros Pharmaceuticals by 23.1% in the 4th quarter. BlackRock Inc. now owns 1,986,130 shares of the company’s stock worth $11,063,000 after purchasing an additional 372,462 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Syros Pharmaceuticals in the 3rd quarter worth approximately $1,791,000. Assenagon Asset Management S.A. acquired a new position in shares of Syros Pharmaceuticals in the 4th quarter worth approximately $502,000. D. E. Shaw & Co. Inc. grew its stake in shares of Syros Pharmaceuticals by 763.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 88,882 shares of the company’s stock worth $496,000 after purchasing an additional 78,591 shares during the last quarter. Finally, Vanguard Group Inc grew its stake in shares of Syros Pharmaceuticals by 4.4% in the 3rd quarter. Vanguard Group Inc now owns 1,044,939 shares of the company’s stock worth $12,446,000 after purchasing an additional 43,562 shares during the last quarter. 67.83% of the stock is currently owned by hedge funds and other institutional investors.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Further Reading: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.